AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04420481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03668782 — intervention group
Intervention type: PROCEDURE
Intervention: Umbilical cord milking
Description: The babies were held at the level of the placenta, while the umbilical cord was milked or cut and clamped.
Study NCT00978445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vMetrics protocol
Description: use vmetrics protocol and device or use standard in clinic monitoring
Study NCT05106660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory Laparoscopic Sleeve Gastrectomy
Description: Same-day discharge
Study NCT00189280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: cream 5%, 5 days out of seven, for 6 weeks
Study NCT05106660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laparoscopic Sleeve Gastrectomy
Description: Next-day discharge
Study NCT00734422 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
Study NCT00734422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
Study NCT02559817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide Dose A
Study NCT02559817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide Dose B
Study NCT02559817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide Dose C
Study NCT02559817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide Approved Adult Dose
Study NCT02559817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study NCT03921281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scalp acupuncture treatment
Description: The parameters for scalp acupuncture are set as follows:~1. Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~2. Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~3. Treatment course: three times a week, 12 weeks in total.
Study NCT03921281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation Treatment
Description: The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
Study NCT01018043 — intervention group
Intervention type: OTHER
Intervention: Adult Cancer Patients
Description: Tracking anemia management in Adult Cancer Patients
Study NCT00890474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion of the BL67 acupoint
Description: Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
Study NCT04558086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
Study NCT03921281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Treatment
Description: The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
Study NCT03864172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual intake + placebo fruit juice
Description: Participants will consume 200 mls of placebo fruit flavoured juice
Study NCT03864172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual intake+SCF fruit juice
Description: Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
Study NCT04558086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photo book
Description: To develop the intervention strategies of hospitalized school-age children with IV placement, using Photo book to further examine the effectiveness of reducing IV pain and fear.
Study NCT02314455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-xylose
Description: There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
Study NCT01788020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, Rituximab, Cyclophosphamide
Study NCT01788020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
Study NCT03864172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adequate calcium + placebo fruit juice
Description: Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
Study NCT03894943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: Patient receive a PET/CT scan of their cerebrum and lumbar spine prior to surgery, 4-6 weeks after surgery and 6 months after surgery
Study NCT03864172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adequate calcium+ SCF fruit juice
Description: Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
Study NCT02284906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets
Study NCT02284906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo-matching tablets
Study NCT00003019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00003019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Study NCT02834403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Nitric oxide synthase inhibitor
Study NCT03894943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Patients undergo a battery of quantitative sensory tests prior to surgery, 4-6 weeks after surgery and 6 months after surgery
Study NCT02834403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Mitotic inhibitor, cytotoxic
Study NCT01532908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir (Part 1)
Description: Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
Study NCT01532908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (Part 2)
Description: One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
Study NCT02783287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder for medication adherence
Description: Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
Study NCT02783287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder for exercise regimen
Description: Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
Study NCT03016702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stress tests during gait task
Description: Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
Study NCT01962753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18FAV45
Description: Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
Study NCT02203279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebase II Fast
Description: It is going to be used a direct relining material
Study NCT02203279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexacryl
Description: This is going to be used as a second direct relining material
Study NCT02203279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vertex
Description: This is going to be used as an indirect relining material
Study NCT04283279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise
Description: Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments.
Study NCT04082741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986318
Description: Specified dose on specified days
Study NCT04082741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Matching BMS-986318
Study NCT04283279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation exercise
Description: Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.
Study NCT04283279 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
Study NCT02834403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Long-acting calcium channel blocker
Study NCT01981044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk surgical mesh
Description: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
Study NCT01878474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
Study NCT01878474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 25 mg
Study NCT01878474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 25, 50, 100 and 150 mg
Study NCT01878474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose in Caucasian men
Study NCT01878474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Age-effect in Caucasian men
Study NCT01878474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gender-effect in Caucasian women
Study NCT01878474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose in Japanese men
Study NCT01197300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: intravenous infusion
Study NCT01055119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Description: duration: 4 month
Study NCT01055119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: duration: 4 month
Study NCT03635879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCTprocal medical food
Description: 32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Study NCT03635879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk/tricaprilin oil blend
Description: 154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
Study NCT03635879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AC-1207
Description: AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Study NCT03635879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AC-1205
Description: AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Study NCT02755688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic Surgical ablation
Description: Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
Study NCT02755688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
Study NCT02834403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor
Study NCT01479985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDM Tool
Description: Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
Study NCT00708201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Study NCT00708201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03635879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AC-1206
Description: AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Study NCT03635879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
Study NCT02884479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-112
Description: Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
Study NCT02884479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
Study NCT03949907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional counseling alone
Description: Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss >10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition.
Study NCT03949907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early supplemental parenteral nutrition plus nutritional counseling
Description: Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated.
Study NCT01872208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV implantation
Description: Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
Study NCT00461331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
Study NCT00461331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
Study NCT01108978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
Study NCT01108978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehypotin
Description: Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
Study NCT02457598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules or tablets administered orally
Study NCT02457598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily
Study NCT02834403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: non-steroidal anti-inflammatory drug
Study NCT02457598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Tablets administered orally
Study NCT00657761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90 mg/12h sc for 7 days
Study NCT00657761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution/12h sc for 7 days
Study NCT02588274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
Study NCT02588274 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo needle
Description: Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
Study NCT00079612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: 800mg daily (2x 400mg tabs)
Study NCT00079612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2x 400mg tabs daily
Study NCT04567316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-radiolabelled BI 1358894
Description: Part 1
Study NCT04567316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Part 2
Study NCT04438044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: ICP-022 The drug product is a white, round, uncoated tablet
Study NCT02155257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Study NCT02155257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Study NCT02155257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo